Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity

Authors: Elamin, Yasir Y., Robichaux, Jacqulyne P., Carter, Brett W., Altan, Mehmet, Tran, Hai, Gibbons, Don L., Heeke, Simon, Fossella, Frank V., Lam, Vincent K., Le, Xiuning, Negrao, Marcelo V., Nilsson, Monique B., Patel, Anisha, Vijayan, R.S.K., Cross, Jason B., Zhang, Jianjun, Byers, Lauren A., Lu, Charles, Cascone, Tina, Feng, Lei, Luthra, Rajyalakshmi, San Lucas, Francis A., Mantha, Geeta, Routbort, Mark, Blumenschein, George, Jr., Tsao, Anne S., Heymach, John V.

Source: In Cancer Cell 11 July 2022 40(7):754-767

Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial

Authors: Kindler, Hedy L ^*, Novello, Silvia, Bearz, Alessandra, Ceresoli, Giovanni L, Aerts, Joachim G J V, Spicer, James, Taylor, Paul, Nackaerts, Kristiaan, Greystoke, Alastair, Jennens, Ross, Calabrò, Luana, Burgers, Jacobus A, Santoro, Armando, Cedrés, Susana, Serwatowski, Piotr, Ponce, Santiago, Van Meerbeeck, Jan P, Nowak, Anna K, Blumenschein, George, Jr, Siegel, Jonathan M, Kasten, Linda, Köchert, Karl, Walter, Annette O, Childs, Barrett H, Elbi, Cem, Hassan, Raffit, Fennell, Dean A ^**

Source: In The Lancet Oncology April 2022 23(4):540-552

Chimeric Antigen Receptor Therapy: How Are We Driving in Solid Tumors?

Authors: Greenbaum, Uri, Yalniz, Fevzi F., Srour, Samer A., Rezvani, Katayoun, Singh, Harjeet, Olson, Amanda, Blumenschein, George, Jr, Hong, David S., Shpall, Elizabeth J., Kebriaei, Partow

Source: In Biology of Blood and Marrow Transplantation October 2020 26(10):1759-1769

Nivolumab versus investigator’s choice in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety in CheckMate 141 by age

Authors: Saba, Nabil F., Blumenschein, George, Jr., Guigay, Joel, Licitra, Lisa, Fayette, Jerome, Harrington, Kevin J., Kiyota, Naomi, Gillison, Maura L., Ferris, Robert L., Jayaprakash, Vijayvel, Li, Li, Brossart, Peter

Source: In Oral Oncology September 2019 96:7-14

Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression

Authors: Ferris, Robert L., Blumenschein, George, Jr., Fayette, Jerome, Guigay, Joel, Colevas, A. Dimitrios, Licitra, Lisa, Harrington, Kevin J., Kasper, Stefan, Vokes, Everett E., Even, Caroline, Worden, Francis, Saba, Nabil F., Docampo, Lara Carmen Iglesias, Haddad, Robert, Rordorf, Tamara, Kiyota, Naomi, Tahara, Makoto, Lynch, Mark, Jayaprakash, Vijayvel, Li, Li, Gillison, Maura L.

Source: In Oral Oncology June 2018 81:45-51

Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-Line Treatment of Anaplastic Lymphoma Kinase Translocation — Positive Advanced Non–Small Cell Lung Cancer (CheckMate 370)

Authors: Spigel, David R., Reynolds, Craig, Waterhouse, David, Garon, Edward B., Chandler, Jason, Babu, Sunil, Thurmes, Paul, Spira, Alexander, Jotte, Robert, Zhu, Jin, Lin, Wen Hong, Blumenschein, George, Jr.

Source: In Journal of Thoracic Oncology May 2018 13(5):682-688

Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial

Authors: Harrington, Kevin J, Ferris, Robert L, Blumenschein, George, Jr, Colevas, A Dimitrios, Fayette, Jérôme, Licitra, Lisa, Kasper, Stefan, Even, Caroline, Vokes, Everett E, Worden, Francis, Saba, Nabil F, Kiyota, Naomi, Haddad, Robert, Tahara, Makoto, Grünwald, Viktor, Shaw, James W, Monga, Manish, Lynch, Mark, Taylor, Fiona, DeRosa, Michael, Morrissey, Laura, Cocks, Kim, Gillison, Maura L, Guigay, Joël

Source: In The Lancet Oncology August 2017 18(8):1104-1115

A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients With Advanced Non–Small Cell Lung Cancer

Authors: Gandara, David R., Leighl, Natasha, Delord, Jean-Pierre, Barlesi, Fabrice, Bennouna, Jaafar, Zalcman, Gerald, Infante, Jeffrey R., Reckamp, Karen L., Kelly, Karen, Shepherd, Frances A., Mazieres, Julien, Janku, Filip, Gardner, Olivia S., Mookerjee, Bijoyesh, Wu, Yuehui, Cox, Donna S., Schramek, Dan, Peddareddigari, Vijay, Liu, Yuan, D'Amelio, Anthony M., Jr., Blumenschein, George, Jr.

Source: In Journal of Thoracic Oncology March 2017 12(3):556-566

Sorafenib in Lung Cancer: Clinical Developments and Future Directions

Authors: Blumenschein, George, Jr

Source: In Journal of Thoracic Oncology June 2008 3(6) Supplement 2:S124-S127

Poziotinib for Patients With Exon 20 Mutant Non-Small-Cell Lung Cancer: Results From a Phase II Trial.

Authors: Elamin, Yasir Y¹ (AUTHOR), Robichaux, Jacqulyne P¹ (AUTHOR), Carter, Brett W² (AUTHOR), Altan, Mehmet¹ (AUTHOR), Gibbons, Don L¹ (AUTHOR), Fossella, Frank V¹ (AUTHOR), Lam, Vincent K^1,3 (AUTHOR), Patel, Anisha B⁴ (AUTHOR), Negrao, Marcelo V¹ (AUTHOR), Le, Xiuning¹ (AUTHOR), Mott, Frank E¹ (AUTHOR), Zhang, Jianjun¹ (AUTHOR), Feng, Lei⁵ (AUTHOR), Blumenschein, George Jr¹ (AUTHOR), Tsao, Anne S¹ (AUTHOR), Heymach, John V¹ (AUTHOR)

Source: Journal of Clinical Oncology. 3/1/2022, Vol. 40 Issue 7, p702-709. 8p.

Insulin-Like Growth Factor Receptor

Authors: Blumenschein, George, Jr

Source: In Journal of Thoracic Oncology November 2011 6(11) Supplement 4:S1799-S1800

Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer.

Authors: Ramanathan, Ramesh K., Von Hoff, Daniel D., Eskens, Ferry, Blumenschein, George, Richards, Donald, Genvresse, Isabelle, Reschke, Susanne, Granvil, Camille, Skubala, Adam, Peña, Carol, Mross, Klaus, Blumenschein, George Jr

Source: Targeted Oncology; Apr2020, Vol. 15 Issue 2, p163-174, 12p

Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial.

Authors: Haddad, Robert, Concha‐Benavente, Fernando, Blumenschein, George, Fayette, Jerome, Guigay, Joel, Colevas, A. Dimitrios, Licitra, Lisa, Kasper, Stefan, Vokes, Everett E., Worden, Francis, Saba, Nabil F., Tahara, Makoto, Jayaprakash, Vijayvel, Lynch, Mark, Li, Li, Gillison, Maura L., Harrington, Kevin J., Ferris, Robert L., Concha-Benavente, Fernando, Blumenschein, George Jr

Source: Cancer (0008543X); Sep2019, Vol. 125 Issue 18, p3208-3218, 11p

Subject Terms: SQUAMOUS cell carcinoma, CLINICAL trials, TERMINATION of treatment, SUBGROUP analysis (Experimental design), NECK

This result is not displayed to guests.
Login for full access.

MINI01.02: Response and Plasma Genotyping from Phase I/II Trial of Ensartinib (X-396) in Patients (pts) with ALK+ NSCLC: Topic: Medical Oncology

Authors: Horn, Leora, Wakelee, Heather, Reckamp, Karen L., Blumenschein, George, Jr., Infante, Jeffrey R., Carter, Corey A., Waqar, Saiama N., Neal, Joel W., Harrow, Kimberly, Gockerman, Jon P., Dukart, Gary, Liang, Chris, Gibbons, James L., Hernandez, Jennifer, Newman-Eerkes, Tera, Lim, Lee, Lovly, Christine M.

Source: In Journal of Thoracic Oncology November 2016 11(11) Supplement:S256-S257

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

P3-065: A lead-in safety study of erlotinib combined with sutinib for the treatment of metastatic non-small cell lung cancer (NSCLC)

Authors: Blumenschein, George, Jr, Robert, F, Melnyk, O, Sutherland, Kristin C., Tye, Lesley, Wang, Erjian, Chao, Richard, Fossella, Frank V.

Source: In Journal of Thoracic Oncology August 2007 2(8) Supplement:S705-S705

Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: CheckMate 153.

Authors: Waterhouse, David M¹ (AUTHOR), Garon, Edward B² (AUTHOR), Chandler, Jason³ (AUTHOR), McCleod, Michael⁴ (AUTHOR), Hussein, Maen⁵ (AUTHOR), Jotte, Robert⁶ (AUTHOR), Horn, Leora⁷ (AUTHOR), Daniel, Davey B⁸ (AUTHOR), Keogh, George⁹ (AUTHOR), Creelan, Ben¹⁰ (AUTHOR), Einhorn, Lawrence H¹¹ (AUTHOR), Baker, Justin¹² (AUTHOR), Kasbari, Samer¹³ (AUTHOR), Nikolinakos, Petros¹⁴ (AUTHOR), Babu, Sunil¹⁵ (AUTHOR), Couture, Felix¹⁶ (AUTHOR), Leighl, Natasha B¹⁷ (AUTHOR), Reynolds, Craig¹⁸ (AUTHOR), Blumenschein, George Jr¹⁹ (AUTHOR), Gunuganti, Vijay²⁰ (AUTHOR)

Source: Journal of Clinical Oncology. 9/10/2020, Vol. 38 Issue 26, pJCO2000131-JCO2000131. 1p.